Background: Ovarian cancer (OC) is the 5th leading cause of cancer death among women, and presents
poor prognosis when diagnosed at a late stage. Despite recent advances in OC managements,
patients can acquire chemoresistance after first-line treatments, and tumor progression
take place. Novel therapies targeting the immunological system have emerged as promising
complementary therapies for OC. The Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate
anhydride (P-MAPA) immunotherapy and human recombinant interleukin-12 (IL-12) have
showed important effects in solid tumors and might be largely useful against OC development.
To evaluate the effects of P-MAPA and IL-12 alone and the combination therapy (P-MAPA
+ IL-12) on toll-like receptor 2 and 4 (TLR2 and 4)-mediated signaling pathway, cytokine/chemokine
secretion and migratory potential in OC cells.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P05.04
Identification
Copyright
© 2018 Published by Elsevier Inc.
